Results 31 to 40 of about 29,210 (297)

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma

Cell Death Discovery, 2022
Altered features of tumor cells acquired across therapy can result in the survival of treatment-resistant clones that may cause minimal residual disease (MRD).
Viktoria Fuhr, Shanice Heidenreich, Mugdha Srivastava, Angela Riedel, Johannes Düll, Elena Gerhard-Hartmann, Andreas Rosenwald, Hilka Rauert-Wunderlich   +7 more
doaj   +1 more source

Ibrutinib for B cell malignancies [PDF]

Experimental Hematology & Oncology, 2014
Research over the role of Bruton's agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies. Down-regulation of BTK activity is an attractive novel strategy for treating patients with B-cell malignancies. Ibrutinib (PCI-32765),
Delong Liu, Aileen Novero, Yamei Chen, Yamei Chen, Pavan M Ravella, George Dous   +5 more
openaire   +3 more sources

EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma. [PDF]

Hemasphere
Abstract Mantle cell lymphoma (MCL) is a relatively rare B‐cell lymphoma subtype, with a higher incidence among males and a median age of 70 years at diagnosis. MCL is characterized by clinically diverse behavior, from indolent disease to extremely aggressive, related to the presence of biological risk factors such as proliferation rate and TP53 ...
Jerkeman M, Aurer I, Campo E, Cheah CY, Clark J, Doorduijn J, Eyre TA, Fehr M, Giné E, Gomes da Silva M, Klener P, Ladetto M, Ribrag V, Shpilberg O, Walewski J, Dreyling M, EHA Guidelines Committee and the European MCL Network.   +16 more
europepmc   +2 more sources

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Journal of Clinical Oncology, 2023
PURPOSE In GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL).
T. Munir, C. Moreno, C. Owen, G. Follows, O. Benjamini, A. Janssens, M. Levin, A. Osterborg, T. Robak, M. Šimkovič, D. Stevens, S. Voloshin, V. Vorobyev, M. Yağcı, L. Ysebaert, K. Qi, Qianya Qi, Lori Parisi, Srimathi Srinivasan, N. Schuier, K. Baeten, A. Howes, D. B. Caces, C. Niemann, A. Kater   +24 more
semanticscholar   +1 more source

Drug Review: Ibrutinib [PDF]

Indian Journal of Medical and Paediatric Oncology, 2020
AbstractIbrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Importantly, it has expanded the armamentarium for those patients who are refractory to conventional chemoimmunotherapy.
openaire   +2 more sources

A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY.

Blood, 2020
Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation BTK inhibitor, with zanubrutinib, a
C. Tam, Stephen Samuel Opat, S. D’Sa, W. Jurczak, Hui-Peng Lee, G. Cull, R. Owen, P. Marlton, B. Wahlin, R. G. Sanz, H. McCarthy, S. Mulligan, A. Tedeschi, J. Castillo, J. Czyż, C. Fernández de Larrea, D. Belada, E. Libby, J. Matous, M. Motta, T. Siddiqi, M. Tani, M. Trněný, M. Minnema, C. Buske, V. Leblond, J. Trotman, W. Chan, J. Schneider, S. Ro, A. Cohen, Jane E. Huang, M. Dimopoulos   +32 more
semanticscholar   +1 more source

Ibrutinib suppresses LPS-induced neuroinflammatory responses in BV2 microglial cells and wild-type mice

Journal of Neuroinflammation, 2018
Background The FDA-approved small-molecule drug ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL). Ibrutinib inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling.
Hye Yeon Nam, Jin Han Nam, Gwangho Yoon, Ju-Young Lee, Youngpyo Nam, Hye-Jin Kang, Hyun-Ji Cho, Jeongyeon Kim, Hyang-Sook Hoe   +8 more
doaj   +1 more source

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial

Blood Advances, 2023
Key Points • In the PHOENIX trial, the addition of ibrutinib to R-CHOP did not improve the survival of patients with previously untreated non-GCB DLBCL.• This study identified a patient subset with high BCL2/MYC coexpression using RNA sequencing, with ...
P. Johnson, S. Balasubramanian, B. Hodkinson, S. Shreeve, Steven Sun, Srimathi Srinivasan, A. Steele, J. Vermeulen, L. Sehn, W. Wilson   +9 more
semanticscholar   +1 more source

Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

Haematologica, 2017
The first-in-class Bruton’s tyrosine kinase inhibitor ibrutinib has proven clinical benefit in B-cell malignancies; however, atrial fibrillation (AF) has been reported in 6–16% of ibrutinib patients.
Jennifer R. Brown, Javid Moslehi, Susan O’Brien, Paolo Ghia, Peter Hillmen, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Thomas J. Kipps, Steven Coutre, Marie-Sarah Dilhuydy, Paula Cramer, Alessandra Tedeschi, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Angela Howes, Michael Todd, Jessica Vermeulen, Danelle F. James, Fong Clow, Lori Styles, Rudy Valentino, Mark Wildgust, Michelle Mahler, Jan A. Burger   +26 more
doaj   +1 more source

Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax

Clinical Cancer Research, 2023
Purpose: Mutations in BTK, PLCG2, and BCL2 have been reported in patients with progressive disease (PD) on continuous single-agent BTK or BCL2 inhibitor treatment.
Nitin Jain, Lisa J Croner, J. Allan, Tanya Siddiqi, A. Tedeschi, X. Badoux, K. Eckert, L. Cheung, Anwesha Mukherjee, J. P. Dean, E. Szafer-Glusman, J. F. Seymour   +11 more
semanticscholar   +1 more source